Earnings Report Digest

$PM has released its earnings report, showcasing a strong performance in Q4 2024 and overall growth for the year. Key highlights include an organic net revenue growth of +9.8% and a robust +14.9% increase in organic operating income. However, there are currency and supply chain headwinds to address. 📈

$AZN has released its latest earnings report, showcasing robust growth and developments. Total revenue surged 21% year-over-year, with a core EPS increase of 19%. While the company reported potential risks in China, ongoing investigations could impact their operations. Highlights include steady growth across various therapy areas and expectations of continued innovation. ⚕️💰 Investors should note the evolving market conditions while anticipating future opportunities. For detailed insights, visit valueverge.com/AZN.

$LIN reports solid Q4 results with a flat sales of $8.3B and a margin of 29.9%. ⚖️ Key metrics show 25.9% return on capital and a 10% EPS growth, despite FX headwinds. Valuation aligns with strong historical performance, but future FX risks loom.

$LLY has just released its Q4 2024 earnings report, highlighting robust revenue growth of 45% compared to Q4 2023, driven by strong performance from Mounjaro and Zepbound. Key risks include the competitive landscape in the incretin market and ongoing pricing pressures.

$AMZN has released its Q4 2024 earnings, showing 10% year-over-year revenue growth to $187.8 billion despite a significant foreign exchange headwind. Operating income surged 61% to $21.2 billion, reflecting improved profitability. Key insights reveal strong growth in AWS by 19% YOY and advertising revenue up 18%.

Trending stocks, Feb 6 2025

$JCI has released its Q4 fiscal 2024 earnings, showing strong performance with a 10% organic revenue growth and significant margin expansion. Key stats include an adjusted EPS growth of 22% YoY and a robust 96% adjusted free cash flow conversion. Despite risks from restructuring and capital deployment, the future looks promising with a record backlog of $13.1 billion, driven by data center demand. For fiscal 2025, guidance suggests adjusted EPS between $3.40 and $3.50, with expected growth of 6%-9%. Explore more details at valueverge.com/JCI. 📈💼

$ARES has released its earnings report for Q4 and year-end 2024, showcasing a strong performance with notable increases in assets under management (AUM) and fee-related earnings. AUM rose by 16% to over $484 billion, while management fees climbed to a record $781 million. The firm has increased its quarterly dividend by 20%, reflecting confidence in future growth. However, a dynamic market and potential regulatory changes pose risks. Future opportunities include expanding direct lending strategies and acquisitions. 🌐💵 Check details at valueverge.com/ARES.

$EQNR has released its latest earnings report, showcasing a strong quarterly performance. Here's a quick look at the key stats: Return on Capital Employed is at 21%, with cash flow from operations hitting $18 billion. Risks include fluctuating energy prices and geopolitical tensions, but the company remains committed to delivering sustainable growth and competitive returns.

🚨 $GSK announces its 2024 earnings results, showcasing a sales increase of 8% to over £31 billion, driven by specialty medicines and significant profit growth📈. Core operating profit rose by 13%, with core EPS up 12%. However, vaccine sales faced challenges, impacting short-term growth forecasts. 💉 The outlook for 2025 anticipates continued robust growth, particularly in specialty medicines, with five new product approvals expected. 📊 For more details, visit valueverge.com/GSK.